​

Verona Pharma (VRNA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VRNA Stock Forecast

Verona Pharma (VRNA) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $120.00, with a high of $170.00 and a low of $80.00. This represents a 14.19% increase from the last price of $105.09.

- $40 $80 $120 $160 $200 High: $170 Avg: $120 Low: $80 Last Closed Price: $105.09

VRNA Stock Rating

Verona Pharma stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (64.29%), 5 Hold (35.71%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 5 9 Strong Sell Sell Hold Buy Strong Buy

VRNA Price Target Upside V Benchmarks

TypeNameUpside
StockVerona Pharma14.19%
SectorHealthcare Stocks 18.80%
IndustryBiotech Stocks 54.28%

Price Target Trends

1M3M12M
# Anlaysts239
Avg Price Target$138.50$145.67$95.44
Last Closing Price$105.09$105.09$105.09
Upside/Downside31.79%38.61%-9.18%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 2529---11
Jun, 2537---10
May, 2537---10
Apr, 2535---8
Mar, 2535---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 14, 2025Raghuram SelvarajuH.C. Wainwright$107.00$104.672.23%1.82%
Jun 30, 2025Wolfe Research$170.00$94.5879.74%61.77%
Jun 23, 2025Piper Sandler$160.00$97.0564.86%52.25%
Apr 21, 2025Cantor Fitzgerald$80.00$60.0733.18%-23.87%
Feb 28, 2025Roth Capital$83.00$69.6319.20%-21.02%
Jan 10, 2025Boobalan PachaiyappanRoth Capital$68.00$45.2050.44%-35.29%
Jan 08, 2025Tiago FauthWells Fargo$74.00$49.5549.34%-29.58%
Nov 05, 2024Raghuram SelvarajuH.C. Wainwright$42.00$38.399.40%-60.03%
Jul 22, 2024Edward NashCanaccord Genuity$37.00$22.9561.22%-64.79%
Jun 27, 2024Raghuram SelvarajuH.C. Wainwright$36.00$14.69145.06%-65.74%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 14, 2025H.C. WainwrightBuyNeutraldowngrade
Jul 09, 2025Cowen & Co.BuyHolddowngrade
Jun 30, 2025Wolfe ResearchOutperforminitialise
Jun 23, 2025Piper SandlerOverweightOverweighthold
Apr 28, 2025Cowen & Co.Buyinitialise
Apr 21, 2025Cantor FitzgeraldOverweightinitialise
Feb 28, 2025H.C. WainwrightBuyBuyhold
Jan 08, 2025Wells FargoOverweightOverweighthold
Jan 08, 2025BTIGBuyBuyhold
Oct 03, 2024Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.12$-0.13$-0.09$-0.27----
Avg Forecast$-0.77$-0.15$-0.07$-0.46$0.04$0.39$0.96$1.35
High Forecast$-0.16$-0.10$-0.07$-0.43$0.93$1.21$1.81$1.75
Low Forecast$-1.44$-0.25$-0.08$-0.51$-1.04$0.02$0.23$0.66
Surprise %-84.42%-13.33%28.57%-41.30%----

Revenue Forecast

$0 $200M $400M $600M $800M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$40.00M$458.00K-$42.28M----
Avg Forecast$29.65M$6.79M$376.47K$28.30M$186.84M$374.59M$550.06M$774.06M
High Forecast$49.52M$10.71M$463.55K$28.47M$214.88M$379.24M$561.45M$953.09M
Low Forecast$11.56M$5.10M$229.40K$28.21M$120.78M$369.94M$538.68M$471.68M
Surprise %34.90%-93.26%-49.41%----

Net Income Forecast

$-1B $-500M $0 $500M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-55.57M$-68.70M$-54.37M$-173.42M----
Avg Forecast$-61.17M$-11.51M$-47.75M$-299.37M$-8.41M$91.72M$172.75M$853.54M
High Forecast$-12.66M$-7.78M$-44.90M$-275.42M$592.87M$766.65M$1.15B$1.11B
Low Forecast$-114.45M$-20.12M$-50.60M$-323.32M$-658.75M$10.22M$148.22M$420.08M
Surprise %-9.16%497.10%13.86%-42.07%----

VRNA Forecast FAQ

Is Verona Pharma stock a buy?

Verona Pharma stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Verona Pharma is a favorable investment for most analysts.

What is Verona Pharma's price target?

Verona Pharma's price target, set by 14 Wall Street analysts, averages $120 over the next 12 months. The price target range spans from $80 at the low end to $170 at the high end, suggesting a potential 14.19% change from the previous closing price of $105.09.

How does Verona Pharma stock forecast compare to its benchmarks?

Verona Pharma's stock forecast shows a 14.19% upside, underperforming the average forecast for the healthcare stocks sector (18.80%) and underperforming the biotech stocks industry (54.28%).

What is the breakdown of analyst ratings for Verona Pharma over the past three months?

  • July 2025: 18.18% Strong Buy, 81.82% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Verona Pharma’s EPS forecast?

Verona Pharma's average annual EPS forecast for its fiscal year ending in December 2025 is $0.04, marking a -114.81% decrease from the reported $-0.27 in 2024. Estimates for the following years are $0.39 in 2026, $0.96 in 2027, and $1.35 in 2028.

What is Verona Pharma’s revenue forecast?

Verona Pharma's average annual revenue forecast for its fiscal year ending in December 2025 is $186.84M, reflecting a 341.93% increase from the reported $42.28M in 2024. The forecast for 2026 is $374.59M, followed by $550.06M for 2027, and $774.06M for 2028.

What is Verona Pharma’s net income forecast?

Verona Pharma's net income forecast for the fiscal year ending in December 2025 stands at $-8.409M, representing a -95.15% decrease from the reported $-173M in 2024. Projections indicate $91.72M in 2026, $172.75M in 2027, and $853.54M in 2028.